A Phase 1/2 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC).

Trial Profile

A Phase 1/2 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2014

At a glance

  • Drugs Elesclomol (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2014 According to ClinicalTrials.gov record trial status changed from suspended to completed.
    • 27 Feb 2009 Status changed from active, no longer recruiting to discontinued. The reasons for the decision to suspend this trial have been reported in a Synta Pharmaceuticals media release.
    • 16 Dec 2008 New source identified and integrated (ClinicalTrials.gov record NCT00808418).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top